The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 21, 2025
Filed:
Mar. 10, 2020
Applicant:
Fred Hutchinson Cancer Center, Seattle, WA (US);
Inventors:
Thomas M. Schmitt, Seattle, WA (US);
Aude G. Chapuis, Seattle, WA (US);
Philip D. Greenberg, Mercer Island, WA (US);
Assignee:
FRED HUTCHINSON CANCER CENTER, Seattle, WA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2025.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/4243 (2025.01); A61P 35/00 (2018.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); A61K 2239/49 (2023.05); A61K 2239/54 (2023.05);
Abstract
The present disclosure provides T cell receptors (TCRs) and related binding proteins with high functional avidity against tumor associated antigen p37 from Wilms tumor protein 1 (WT1), T cells expressing such high affinity WT1 specific TCRs, nucleic acids encoding the same, and compositions for use in treating diseases or disorders in which cells overexpress WT1 and/or produce the p37 antigen, such as in cancer.